Replies to post #190 on Cryo Cell International Inc (CCEL)

[Booger Red]

:-)

[MinnieM]

Read this link...it doesn't look like they are sitting on their hands.

CRYO-CELL INTERNATIONAL, INC. REPORTS THIRD QUARTER 2010 RESULTS
Company Reports $2.3 Million Net Income for Third Quarter
Representing a 72% Year over Year Increase in Net Income OLDSMAR, Fla. – October 14, 2010

http://www.sec.gov/Archives/edgar/data/862692/000119312510231001/dex991.htm

An excerpt:

During the third quarter 2010, Cryo-Cell announced that S-Evans Biosciences (SEB), the Company’s exclusive CélleSM menstrual stem cell technology license partner in China has opened a new state-of-the-art laboratory operation and research & development (R&D) facility located in a Hi-Tech park designated to become an epicenter for stem cell and genomics R&D; cellular therapies and stem cell cryopreservation services. The new SEB facility which occupies over 25,000 square feet and includes four Good Manufacturing Practice (cGMP) laboratories and administrative offices is designed to process approximately 10,000 menstrual stem cell samples a year at the height of operational deployment. SEB anticipates that it may build the world’s largest Célle menstrual stem cell bank over the next three to five years. The exclusive Célle technology license agreement with SEB in China and Thailand is expected to provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells. Currently, SEB is conducting three pre-clinical studies for heart disease, type I diabetes and liver disease utilizing menstrual stem cells prepared in SEB and recently reported that the preliminary data are encouraging.

In another major development during the third quarter 2010, the Company announced a R&D collaboration agreement with world renowned stem cell researchers at Monash University in Australia. The partnership will allow scientists from the University’s Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell’s proprietary CélleSM menstrual stem cell technology to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis (MS). Monash researchers believe that the menstrual stem cell may potentially provide a highly prolific, non-invasive and cost-effective alternative cell source in the development of future cellular therapies to treat this debilitating autoimmune disease. Under terms of the research collaboration agreement, the R&D study is funded entirely by Monash and intellectual property that may result from the Célle MS research is expected to be shared equally by both partners.

In view of recent encouraging developments associated with proprietary CélleSM menstrual cell technology, the Company continues to believe that Cryo-Cell’s growth moving forward may possibly be generated from one or more of several promising sources. The Company’s future potential growth drivers may possibly include: fees from Célle processing and storage services; revenues from future therapeutic development that may utilize Célle technology; product diversification; global expansion and strategic acquisition.

“We are very pleased and clearly energized by Cryo-Cell’s performance throughout the third quarter of fiscal 2010 which includes net income of $3.0 million year to date, or $0.26 per basic common share; and profitability in seven of the last eight quarters,” stated Mercedes A. Walton, Chairman and CEO. “Cryo-Cell’s cord blood banking business remains solid and continues to generate strong recurring revenues. In addition, the Company has substantial cash reserves and an expansive technology IP portfolio.

“Strategically and operationally, Cryo-Cell is perhaps at one of the strongest positions in our corporate history. We anticipate continued profitability for the foreseeable future. We also expect that Cryo-Cell’s demonstrably strong and sustained performance, combined with the Company’s vast potential future upside possibly driven by Célle technology; product diversification; global expansion and strategic acquisition, may significantly and positively impact short and longer-term shareholder value,” Walton concluded.

As of August 31, 2010, the Company had $9.0 million in cash, cash equivalents, marketable securities and other investments. The Company had no long-term debt at the end of the quarter.

In Reply to 'Dew'

Why are the people running this company sitting idly by while competetors are gobbling up other cord blood companies. They have $9M in cash and yet have done nothing to increase there market share. If you're not growing your going backwards. Which is what I think CCEL is doing.